

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G

LA JOLLA PHARMACEUTICAL CO
Form SC 13G
February 13, 2002

OMB APPROVAL

OMB Number: 3235-0145
Expires: August 31, 1999
Estimated average burden
hours per response...14.90

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(RULE 13D-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT TO RULE 13D-1(B), (C) AND (D) AND AMENDMENTS THERETO
FILED PURSUANT TO RULE 13D-2(B)

(AMENDMENT NO. _____)*
La Jolla Pharmaceuticals

(Name of Issuer)
Common Stock, \$0.01 par value

(Title of Class of Securities)
503459109

(CUSIP Number)
February 9, 2001

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G

POTENTIAL PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER.

SEC 1745 (3-98)

Page 1 of 10 pages

SCHEDULE 13G

ISSUER: La Jolla Pharmaceuticals

CUSIP NO.: 503459109

1. Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

J.P. Morgan Partners (BHCA), L.P. (formerly known as Chase Equity Associates, L.P.)
13-3371826

2. Check the Appropriate Box if a Member of a Group (See Instructions)

- (a)
(b)

3. SEC Use Only

4. Citizenship or Place of Organization Delaware

Table with 4 columns: Description, Item Number, Power Type, and Amount. Rows include: Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 2,055,000; 6. Shared Voting Power; 7. Sole Dispositive Power 2,055,000; 8. Shared Dispositive Power.

9. Aggregate Amount Beneficially Owned by Each Reporting Person 2,055,000

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9) 5.8%

12. Type of Reporting Person (See Instructions)

PN

.....
.....
.....

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G

.....
.....
.....

SEC 1745 (3-98)

Page 2 of 10 pages

SCHEDULE 13G

ISSUER: La Jolla Pharmaceuticals

CUSIP NO.: 503459109

ITEM 1.

(A) NAME OF ISSUER:

La Jolla Pharmaceuticals

(B) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

6455 Nancy Ridge Drive
San Diego, California 92121

ITEM 2.

(A) NAME OF PERSON FILING:

J.P. Morgan Partners (BHCA), L.P.

Supplemental information relating to the ownership and control of the person filing this statement is included in Exhibit 2(a) attached hereto.

(B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

1221 Avenue of the Americas
New York, New York 10020

(C) CITIZENSHIP:

Delaware

(D) TITLE OF CLASS OF SECURITIES (OF ISSUER):

Common Stock, par value \$0.01 per share

(E) CUSIP NUMBER:

503459109

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.SS.240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

Not applicable.

ITEM 4. OWNERSHIP

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G

- (A) AMOUNT BENEFICIALLY OWNED:
2,055,000
- (B) PERCENT OF CLASS:
5.8% (as of December 31, 2001).

SEC 1745 (3-98)

Page 3 of 10 pages

SCHEDULE 13G

ISSUER: La Jolla Pharmaceuticals

CUSIP NO.: 503459109

- (C) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
- (i) Sole power to vote or to direct the vote: 2,055,000 shares of Common Stock.
 - (ii) Shared power to vote or to direct the vote: Not applicable.
 - (iii) Sole power to dispose or to direct the disposition of: 2,055,000 shares of Common Stock
 - (iv) Shared power to dispose or to direct the disposition of: Not applicable.

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

Not applicable.

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

Not applicable.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

Not applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

Not applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP

Not applicable.

ITEM 10. CERTIFICATION

(a) Not applicable.

(b) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G

in connection with or as a participant in any transaction having that purpose or effect.

SEC 1745 (3-98)

Page 4 of 10 pages

SCHEDULE 13G

ISSUER: La Jolla Pharmaceuticals

CUSIP NO.: 503459109

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February _____, 2002

J.P. MORGAN PARTNERS (BHCA), L.P.

By: JPMP Master Fund Manager, L.P.,
its General Partner

By: JPMP Capital Corp.,
its General Partner

By: /s/ JEFFREY C. WALKER

Name: Jeffrey C. Walker
Title: President

SEC 1745 (3-98)

Page 5 of 10 pages

SCHEDULE 13G

ISSUER: La Jolla Pharmaceuticals

CUSIP NO.: 503459109

EXHIBIT 2(A)

This statement is being filed by J.P. Morgan Partners (BHCA), L.P. (formerly known as Chase Equity Associates, L.P.), a Delaware limited partnership (hereinafter referred to as "JPMP (BHCA)"), whose principal business office is located at 1221 Avenue of the Americas, New York, New York 10020. JPMP (BHCA) is engaged in the venture capital and leveraged buyout business. The general partner of JPMP (BHCA) is JPMP Master Fund Manager, L.P. (formerly known as Chase Capital Partners, a New York general partnership), a Delaware limited partnership (hereinafter referred to as "JPMP Master Fund"), whose principal business office is located at the same address as JPMP (BHCA), and is also directly or indirectly (through affiliates) engaged in the venture capital and leveraged buyout business. The general partner of JPMP Master Fund is JPMP Capital Corp. (formerly known as Chase Capital Corporation), a New York corporation (hereinafter referred to as "JPMP Capital Corp."), whose principal

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G

business office is located at the same address as JPMP (BHCA), and is also engaged in the venture capital and leveraged buyout business. Set forth in Schedule A hereto and incorporated herein by reference are the names, business addresses, principal occupations and employments of each executive officer and director of JPMP Capital Corp.

JPMP Capital Corp. is a wholly owned subsidiary of J.P. Morgan Chase & Co. (formerly known as The Chase Manhattan Corporation), a Delaware corporation (hereinafter referred to as "JP Morgan Chase") which is engaged (primarily through subsidiaries) in the commercial banking business with its principal office located at 270 Park Avenue, New York, New York 10017. Set forth in Schedule B hereto and incorporated herein by reference are the names, business addresses, principal occupations and employments of each executive officer and director of JP Morgan Chase.

SEC 1745 (3-98)

Page 6 of 10 pages

SCHEDULE 13G

ISSUER: La Jolla Pharmaceuticals

CUSIP NO.: 503459109

SCHEDULE A

JPMP CAPITAL CORP.

EXECUTIVE OFFICERS(1)

| | |
|--------------------------|---------------------------|
| President | Jeffrey C. Walker* |
| Executive Vice President | Mitchell J. Blutt, M.D.* |
| Executive Vice President | Arnold L. Chavkin* |
| Executive Vice President | John M.B. O'Connor* |
| Managing Director | Dr. Dana Beth Ardi* |
| Managing Director | John R. Baron* |
| Managing Director | Christopher C. Behrens* |
| Managing Director | David S. Britts* |
| Managing Director | Julie Casella-Esposito* |
| Managing Director | Jerome Colonna* |
| Managing Director | Rodney A. Ferguson* |
| Managing Director | David L. Ferguson* |
| Managing Director | David Gilbert* |
| Managing Director | Eric A. Green* |
| Managing Director | Michael R. Hannon* |
| Managing Director | Donald J. Hofmann, Jr. * |
| Managing Director | W. Brett Ingersoll* |
| Managing Director | Alfredo Irigoin* |
| Managing Director | Andrew Kahn* |
| Managing Director | Jonathan R. Lynch* |
| Managing Director | Thomas G. Mendell* |
| Managing Director | Stephen P. Murray* |
| Managing Director | Timothy Purcell* |
| Managing Director | Faith Rosenfeld* |
| Managing Director | Robert R. Ruggiero, Jr. * |
| Managing Director | Susan L. Segal* |
| Managing Director | Kelly Shackelford* |
| Managing Director | Shahan D. Soghikian* |
| Managing Director | Patrick J. Sullivan* |

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G

| | |
|--|--------------------------|
| Managing Director | Timothy J. Walsh* |
| Managing Director | Richard D. Waters, Jr. * |
| Managing Director | Damion E. Wicker, M.D.* |
| Managing Director | Eric R. Wilkinson* |
| Senior Vice President | Marcia Bateson* |
| Senior Vice President and Assistant Secretary | Mounir Nahas* |
| Senior Vice President and Assistant Secretary | Stephen Skoczylas* |
| Senior Vice President, Treasurer and Assistant Secretary | Elisa R. Stein* |
| Vice President and Assistant Secretary | Jeffrey Glatt* |
| Vice President and Assistant Secretary | Puneet Gulati* |
| Vice President and Assistant Secretary | Sandra King* |
| Vice President and Assistant Secretary | Scott Kraemer* |
| Secretary | Anthony J. Horan** |
| Assistant Secretary | Robert C. Carroll** |
| Assistant Secretary | Denise G. Connors** |

(1) Each of whom is a United States citizen except for Messrs. Britts, Irigoien, and Soghikian.

* Principal occupation is employee and/or officer of J.P. Morgan Partners, LLC. Business address is c/o J.P. Morgan Partners, LLC, 1221 Avenue of the Americas, New York, New York 10020.

** Principal occupation is employee or officer of J.P. Morgan Chase & Co. Business address is c/o J.P. Morgan Chase & Co., 270 Park Avenue, New York, New York 10017.

SEC 1745 (3-98)

Page 7 of 10 pages

SCHEDULE 13G

ISSUER: La Jolla Pharmaceuticals

CUSIP NO.: 503459109

DIRECTORS (1)

William B. Harrison**
Jeffrey C. Walker*

(1) Each of whom is a United States citizen except for Messrs. Britts, Irigoien, and Soghikian.

* Principal occupation is employee and/or officer of J.P. Morgan Partners, LLC. Business address is c/o J.P. Morgan Partners, LLC, 1221 Avenue of the Americas, New York, New York 10020.

** Principal occupation is employee or officer of J.P. Morgan Chase & Co. Business address is c/o J.P. Morgan Chase & Co., 270 Park Avenue, New York, New York 10017.

SEC 1745 (3-98)

Page 8 of 10 pages

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G

SCHEDULE 13G

ISSUER: La Jolla Pharmaceuticals

CUSIP NO.: 503459109

SCHEDULE B

J.P. MORGAN CHASE & CO.

EXECUTIVE OFFICERS(1)

| | |
|---|------------------------|
| Chairman of the Board and Chief Executive Officer | William B. Harrison Jr |
| Vice Chairman; Co-Chief Executive Officer, Investment Bank | Geoffrey T. Boisi * |
| Vice Chairman; Head of Retail and Middle Market, Financial Services and Management and Private Banking | David A. Coulter* |
| Director of Human Resources | John J. Farrell* |
| Vice Chairman; Chairman, Investment Bank | Walter A. Gubert* |
| Vice Chairman | Thomas B. Ketchum* |
| Director of Corporate Marketing and Communications | Frederick W. Hill* |
| Vice Chairman; Co-Chief Executive Officer, Investment Bank | Donald H. Layton* |
| Vice Chairman | James B. Lee Jr. * |
| General Counsel | William H. McDavid* |
| Vice Chairman; Head of Finance, Risk Management and Administration | Marc J. Shapiro* |
| Vice Chairman | Jeffrey C. Walker** |
| Executive Vice President; General Auditor | William J. Moran* |
| Chief Financial Officer | Dina Dublon* |
| Executive Vice President; Head of Market Risk Management | Lesley Daniels Webster |
| Managing Director; Corporate Treasurer | David B. Edelson* |
| Managing Director; Head of Credit Risk Policy | Suzanne Hammett* |
| Corporate Secretary | Anthony James Horan* |
| Senior Vice President; Chief Compliance Officer | Gregory S. Meredith* |
| Controller | Joseph L. Scalfani* |
| Assistant Corporate Secretary | James C. Berry* |

DIRECTORS(1)

| NAME | PRINCIPAL OCCUPATION OR EMPLOYMENT; BUSINESS OR RESIDENCE ADDRESS |
|-----------------------|---|
| Hans W. Becherer | Retired Chairman of the Board and Chief Executive Officer Deere & Company One John Deere Place Moline, IL 61265 |
| Riley P. Bechtel | Chairman and Chief Executive Officer Bechtel Group, Inc. P.O. Box 193965 San Francisco, CA 94119-3965 |
| Frank A. Bennack, Jr. | President and Chief Executive Officer The Hearst Corporation 959 Eighth Avenue New York, New York 10019 |

(1) Each of whom is a United States citizen.

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G

- * Principal occupation is employee or officer of J.P. Morgan Chase & Co. Business address is c/o J.P. Morgan Chase & Co., 270 Park Avenue, New York, New York 10017.
- ** Principal occupation is employee and/or officer of J.P. Morgan Partners, LLC. Business address is c/o J.P. Morgan Partners, LLC, 1221 Avenue of the Americas, New York New York 10020.

SEC 1745 (3-98)

Page 9 of 10 pages

SCHEDULE 13G

ISSUER: La Jolla Pharmaceuticals

CUSIP NO.: 503459109

| NAME | PRINCIPAL OCCUPATION OR EMPLOYMENT; BUSINESS OR RESIDENCE ADDRESS |
|--------------------------|---|
| Lawrence A. Bossidy | Chairman of the Board Honeywell International .O. Box 3000 Morristown, NJ 07962-2245 |
| M. Anthony Burns | Chairman of the Board Ryder System, Inc. 3600 N.W. 82nd Avenue Miami, Florida 33166 |
| H. Laurence Fuller | Retired Co-Chairman BP Amoco p.l.c. 1111 Warrenville Road, Suite 25 Chicago, Illinois 60563 |
| Ellen V. Futter | President and Trustee American Museum of Natural History Central Park West at 79th Street New York, NY 10024 |
| William H. Gray, III | President and Chief Executive Officer The College Fund/UNCF 9860 Willow Oaks Corporate Drive P.O. Box 10444 Fairfax, Virginia 22031 |
| William B. Harrison, Jr. | Chairman of the Board and Chief Executive Officer J.P. Morgan Chase & Co. 270 Park Avenue, 8th Floor New York, New York 10017-2070 |
| Helene L. Kaplan | Of Counsel Skadden, Arps, Slate, Meagher & Flom LLP Four Times Square New York, New York 10036 |
| Lee R. Raymond | Chairman of the Board and Chief Executive Officer Exxon Mobil Corporation 5959 Las Colinas Boulevard Irving, TX 75039-2298 |

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G

John R. Stafford Chairman of the Board
American Home Products Corporation
5 Giralda Farms
Madison, New Jersey 07940

Lloyd D. Ward Chief Executive Officer
U.S. Olympic Committee
One Olympic Plaza
Colorado Springs, CO 80909

Marina v.N. Whitman Professor of Business Administration and Public Policy
The University of Michigan
School of Public Policy
411 Lorch Hall, 611 Tappan Street
Ann Arbor, MI 48109-1220

SEC 1745 (3-98)

Page 10 of 10 pages